Boston Scientific (BSX) director granted 879 restricted shares in lieu of cash

Rhea-AI Filing Summary

Boston Scientific director Christophe Pierre Weber reported receiving two restricted stock grants as a non-employee director. He acquired 556 shares of common stock as an initial equity award with an approximate value of $42,419.50, prorated under the company’s non-employee director compensation program.

Weber also received 323 restricted shares in lieu of 100% of his prorated yearly cash retainer, with an approximate value of $24,662.50. Both grants were based on the closing stock price on the grant date and are scheduled to vest in full at the company’s 2026 annual meeting of stockholders.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Weber Christophe Pierre

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	556	$0.00	--
Grant/Award	Common Stock	323	$0.00	--

Holdings After Transaction: Common Stock — 556 shares (Direct)

Footnotes (1)

1. Grant of restricted stock to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. The grant of restricted stock vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $42,419.50 (representing 100% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant. Grant of restricted stock in lieu of 100% yearly cash compensation, following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. Reflects a value of approximately $24,662.50 (representing 100% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weber Christophe Pierre

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MA 01752-1234

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		556	A	$0.0000(1)	556	D
Common Stock	03/02/2026		A		323	A	$0.0000(2)	879	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted stock to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. The grant of restricted stock vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $42,419.50 (representing 100% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant.

2. Grant of restricted stock in lieu of 100% yearly cash compensation, following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. Reflects a value of approximately $24,662.50 (representing 100% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant.

	/s/ Susan Thompson, Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BSX director Christophe Pierre Weber report?

Christophe Pierre Weber reported receiving two grants of restricted stock in Boston Scientific common shares as a non-employee director. The awards were granted upon his initial Board appointment and are structured under the company’s standard non-employee director compensation program, with vesting tied to the 2026 annual meeting.

How many Boston Scientific (BSX) shares did Christophe Pierre Weber acquire?

Christophe Pierre Weber acquired a total of 879 restricted shares of Boston Scientific common stock. One grant covered 556 shares as an equity award, and a second grant covered 323 shares issued instead of cash retainer payments, both based on the closing price on the grant date.

What is the dollar value of the restricted stock awards to BSX director Weber?

The restricted stock awards to Christophe Pierre Weber reflect values of about $42,419.50 for the equity award and $24,662.50 for stock in lieu of cash. These amounts represent prorated portions of the annual equity award and cash retainer under Boston Scientific’s director compensation program.

When do Christophe Pierre Weber’s Boston Scientific restricted shares vest?

Christophe Pierre Weber’s restricted stock grants are scheduled to vest in full at the next annual meeting of stockholders. The program specifically references the company’s 2026 annual meeting, aligning vesting with that event under Boston Scientific’s non-employee director compensation framework.

Why did BSX issue restricted stock instead of cash to director Christophe Pierre Weber?

Boston Scientific issued one grant of restricted stock to Christophe Pierre Weber in lieu of 100% of his prorated yearly cash compensation. This aligns with the company’s non-employee director compensation program, which allows cash retainers to be fully replaced by equity based on the stock’s closing price at grant.

How were the Boston Scientific restricted stock amounts for Weber calculated?

The company calculated Christophe Pierre Weber’s restricted stock amounts by dividing prorated compensation values by the closing common stock price on the grant date. Approximately $42,419.50 and $24,662.50 were each divided by that closing price to determine the 556-share and 323-share grants, respectively.